Abstract
The mechanisms through which β-catenin signaling is inhibited during colorectal cancer chemoprevention by nonsteroidal anti-inflammatory agents is incompletely understood. We report that nabumetone decreased uninvolved intestinal mucosal β-catenin levels in the MIN mouse with a concomitant increase in glycogen synthase kinase (GSK)-3β levels, an enzyme that targets β-catenin for destruction. However, in the azoxymethane-treated rat, where β-catenin is frequently rendered GSK-3β-insensitive, nabumetone failed to alter β-catenin levels but did decrease β-catenin nuclear localization and transcriptional activity as gauged by cyclin D1. In conclusion, we demonstrate that the differential mechanisms for β-catenin suppression may be determined, at least partly, by GSK-3β.
Original language | English (US) |
---|---|
Pages (from-to) | 161-169 |
Number of pages | 9 |
Journal | Cancer Letters |
Volume | 217 |
Issue number | 2 |
DOIs | |
State | Published - Jan 20 2005 |
Keywords
- Chemoprevention
- Colon cancer
- Nonsteroidal anti-inflammatory drugs
ASJC Scopus subject areas
- Oncology
- Cancer Research